CHZ868
外观
| 识别信息 | |
|---|---|
| |
| CAS号 | 1895895-38-1 |
| PubChem CID | |
| ChemSpider | |
| ChEBI | |
| 化学信息 | |
| 化学式 | C22H19F2N5O2 |
| 摩尔质量 | 423.42 g·mol−1 |
| 3D模型(JSmol) | |
| |
| |
CHZ868是一种含氮有机氟化合物,化学式C
22H
19F
2N
5O
2,能用作JAK抑制剂,特异性抑制JAK激酶2的活性[1][2][3]。
参考文献
[编辑]- ^ Meyer SC, Keller MD, Chiu S, Koppikar P, Guryanova OA, Rapaport F, et al. CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative Neoplasms. Cancer Cell. July 2015, 28 (1): 15–28. PMC 4503933
. PMID 26175413. doi:10.1016/j.ccell.2015.06.006.
- ^ Kong X, Sun H, Pan P, Li D, Zhu F, Chang S, et al. How Does the L884P Mutation Confer Resistance to Type-II Inhibitors of JAK2 Kinase: A Comprehensive Molecular Modeling Study. Scientific Reports. August 2017, 7 (1). Bibcode:2017NatSR...7.9088K. PMC 5567357
. PMID 28831147. doi:10.1038/s41598-017-09586-3. 已忽略未知参数|article-number=(帮助) - ^ Nair PC, Piehler J, Tvorogov D, Ross DM, Lopez AF, Gotlib J, Thomas D. Next-Generation JAK2 Inhibitors for the Treatment of Myeloproliferative Neoplasms: Lessons from Structure-Based Drug Discovery Approaches. Blood Cancer Discovery. September 2023, 4 (5): 352–364. PMC 10472187
. PMID 37498362. doi:10.1158/2643-3230.BCD-22-0189.